Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Israel / NCT05992363
Recruiting Not applicable

Tandem Polyurethane Stents Compared to Single Silicone Stent for Malignant Ureteral Obstruction

NCT05992363 · tracked via the Priya Life Science Israel tracker
Sponsor
Rabin Medical Center
Phase
Not applicable
Started
2023-12-20
Last updated
2025-07-24

Condition(s) studied

Hydronephrosis; Obstruction, UreterRenal FailureMalignancyUreter ObstructionUreter Stricture

Investigational drug(s) / intervention(s)

ureteral stent\s insertion

ureteral stent\s insertion: ureteral stent\\s insertion in the operating room

Study summary

Malignant ureteral obstruction (MUO) is an extrinsic ureteral obstruction caused by malignant diseases. This study aim to compare tandem 6 Fr Percuflex™ stents and single large-caliber 8Fr silicone stent in patients with MUO. The primary endpoint is stent failure rate. The secondary endpoints are patient comfort, quality of life and overall survival.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * patient with malignant ureteral obstruction Exclusion Criteria: * ureteral obstruction of other causes * Language comprehension or other limitation in giving informed consent

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Rabin Medical Center Petah Tikva Israel Recruiting
Sheba medical center Ramat Gan Israel Recruiting

More Rabin Medical Center trials in Israel

Deep Brain Stimulation Surgery for the Treatment of Refractory Obsessive-Compulsive Disorder Recruiting
Carb Counting vs. Simplified Qualitative Meal-Size Estimation Recruiting
Tb-PSMA-I&T Radionuclide Before Radical Prostatectomy in Patients With Locally Advanced Prostate Cancer - TbeforePROST Trial. Recruiting
Interventional Study to Evaluate the Combination of Palbociclib + Sunitinib as a Treatment for Advanced Solid Tumors Recruiting
Two-fraction Versus Five-fraction Stereotactic Radiotherapy for Localized Prostate Cancer Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05992363 on ClinicalTrials.gov ↗ ← All trials in Israel